Severe asthma and exacerbations

**ASPERGILLUS POLYMERASE CHAIN REACTION TESTING IN THE SEVERE ASThma POPULATION**

JP Farrant, H Wardman, L Holmes, L Chishimba, R Niven. University Hospital South Manchester, Manchester, England

**Background** Allergic Broncho-Pulmonary Aspergillosis (ABPA) is associated with known pulmonary fungal colonisation and proven response to long term anti-fungal therapy. A recent trial at our site, confirmed that anti fungal therapy was effective in a group of patients with Severe Asthma with Fungal Sensitisation (SAFS). Whether these patients have pulmonary fungal colonisation remains unknown. Previous hypotheses have indicated that bowel colonisation causes an allergic reaction leading to broncho-constriction. Our hypothesis is that patients with SAFS, who respond to anti-fungal therapy, do have airway colonisation. Aspergillus polymerase chain reaction (APCR), represent a novel and more sensitive way to detect the presence of Aspergillus.

**Methods** We have performed sputum APCR tests in clinical practice over the last 2–3 years. We reviewed a retrospective cohort of patients attending a Severe Asthma Service, whose results were stored on the Mycology results system. Patient notes were reviewed to determine patient’s total serum IgE’s, IgE’s specific to Aspergillus and anti fungal therapy status.

**Results** 77 results were logged on the microbiology of which 70 cases were available for notes review. Of these 44 (63%) were female with an average age of 57.5 years. 26 had ABPA, 42 SAFS and 2 had neither ABPA nor SAFS, but had severe asthma. Overall 57% of ABPA or SAFS patients were APCR positive. 35% of SAFS patients were APCR positive, this number increased to 68% for those who were not taking anti-fungal therapy at the time of the test. The equivalent numbers for ABPA were 65% and 70% respectively. Neither of the 2 control severe patients had positive APCR. The full data is presented in table 1.

**Abstract S60 Table 1**

<table>
<thead>
<tr>
<th>Treatment Status</th>
<th>Positive Aspergillus PCR</th>
<th>Negative Aspergillus PCR</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABPA On treatment</td>
<td>8 (62%)</td>
<td>5 (38%)</td>
</tr>
<tr>
<td>ABPA Off treatment</td>
<td>7 (70%)</td>
<td>3 (30%)</td>
</tr>
<tr>
<td>SAFS On treatment</td>
<td>10 (43%)</td>
<td>13 (57%)</td>
</tr>
<tr>
<td>SAFS Off treatment</td>
<td>15 (60%)</td>
<td>7 (40%)</td>
</tr>
<tr>
<td>Control Off treatment</td>
<td>0 (0%)</td>
<td>2 (100%)</td>
</tr>
</tbody>
</table>

**Conclusion** This data supports the concept that patients with Severe Asthma with Fungal Sensitisation (SAFS) have pulmonary colonisation with Aspergillus. Suppression of such colonisation and reduced allergic response may then be the mechanism of action for anti-fungal therapy.

**CLINICAL OUTCOMES AND INFLAMMATORY BIOMARKERS IN CURRENT SMOKERS AND EX-SMOKERS WITH SEVERE ASThma**

1NC Thomson, 1R Chaudhuri, 2LG Heaney, 3C Bucknall, 4RM Niven, 5CE Brightling, 6AN Menzies-Gow, 7AH Mansur, 8MC Sharry. Respiratory Medicine, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK; 1Centre for Infection and Immunity, Queen’s University of Belfast, Belfast, UK; 2Glasgow Royal Infirmary, Glasgow, UK; 3University of Manchester University Hospital of South Manchester, Manchester, UK; 4Institute for Lung Health, University of Leicester, Leicester, UK; 5University of Southampton, Southampton, UK; 6Royal Brompton Hospital, London, UK; 7Birmingham Heartlands Hospital, University of Birmingham, Birmingham, UK

**Rationale** Some clinical outcomes are worse in current smokers and ex-smokers with mild to moderate asthma compared to never smokers, but little is known about the influence of smoking status in severe asthma.

**Objectives** The objectives of the analysis were to examine the association of current or previous cigarette smoking with clinical and inflammatory variables in severe asthma.

**Methods** We compared patient demographics, disease characteristics and biomarkers of inflammation in never smokers (n=461, 62.3%), ex-smokers (n=210, 28.4%) and current smokers (n=69, 9.3%) with refractory asthma (n=760) recruited to the British Thoracic Society Severe Asthma Registry.

**Results** Current smokers had poorer asthma control, more unscheduled health care visits, more rescue courses of oral steroids and higher anxiety and depression scale scores than ex-smokers or never smokers. Compared to never smokers, current smokers had a reduced proportion of sputum eosinophils (3.75% and 1.25% respectively) and lower fraction of exhaled nitric oxide (FeNO50) values (35 ppb versus 14 ppb), whereas ex-smokers had an increased proportion of sputum neutrophils (43.8% versus 56.9%), but similar proportion of sputum eosinophils (2.3% and FeNO50 values (35 ppb). Both current and ex-smokers had reduced serum specific IgE levels to some common environmental allergens.

**Conclusion** Current smokers with severe asthma exhibit worse outcomes for a range of clinical and health care variables compared to ex-smokers and never smokers with severe asthma. Inflammatory profiles in sputum and blood differ between current smokers, ex-smokers and never smokers, possibly constituting separate phenotypes of severe asthma, which may influence responses to targeted therapies.

**A SYSTEMATIC REVIEW OF FACTORS ASSOCIATED WITH FUTURE ASThma ATTACKS TO INFORM A RISK ASSESSMENT QUESTIONNAIRE**

1JD Blakey, 2K Woulnough, 3AC James, 4J Fellows, 5M Obeidat, 6V Navaratnam, 7J Stringfellow, 2N Yeoh, 1I Pavord, 5M Thomas, 6S Walker. University of Nottingham, Nottingham, UK; 1SevereBreathe Asthma Unit, Heartlands Hospital, Birmingham, UK; 2University of British Columbia, Vancouver, Canada; 3University of Leicester, Leicester, UK; 4University of Southampton, Southampton, UK; 5Asthma UK, London, UK

**Asthma attacks occur across all subtypes and severities of disease. Accurate quantification of asthma attack risk would enable targeting of interventions with a potential reduction in morbidity, mortality, and costs. We aimed to develop a risk assessment questionnaire underpinned by a systematic literature review.**

We searched major databases up to February 2012 using the terms: asthma AND (exacerbati* OR admission) AND (risk OR predict* OR associat*) NOT review.

Included studies were those in individuals >12 years old with doctor-diagnosed asthma on treatment. Outcomes were asthma attacks defined as: deterioration of symptoms, fall in objective measures of airflow, and need for a short course of augmented asthma therapy OR admission to hospital OR attendance at emergency department. Statistical analysis was carried out using RevMan 5 and SPSS 19.

3536 unique publications were retrieved. After title screening and comparison of abstracts against a standard checklist and age criteria, data extraction was undertaken in duplicate on the remaining 145 papers (see figure).

Of 18 major research themes identified, 8 factors had a consistent and clinically important (OR>1.25) association with asthma attacks across publications free from major bias. The questionnaire derived from these factors is shown below. Simplified weighting is proportional to the effect size when expressed as an odds ratio (in brackets).
S60 Aspergillus Polymerase Chain Reaction Testing in the Severe Asthma Population

JP Farrant, H Wardman, L Holmes, L Chishimba and R Niven

*Thorax* 2012 67: A31
doi: 10.1136/thoraxjnl-2012-202678.066

Updated information and services can be found at:
http://thorax.bmj.com/content/67/Suppl_2/A31.1

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Asthma (1782)
- Epidemiologic studies (1829)

---

Notes